1. Home
  2. NBB vs FLGT Comparison

NBB vs FLGT Comparison

Compare NBB & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Taxable Municipal Income Fund of Beneficial Interest

NBB

Nuveen Taxable Municipal Income Fund of Beneficial Interest

HOLD

Current Price

$15.66

Market Cap

465.9M

Sector

Finance

ML Signal

HOLD

Logo Fulgent Genetics Inc.

FLGT

Fulgent Genetics Inc.

HOLD

Current Price

$18.88

Market Cap

525.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NBB
FLGT
Founded
N/A
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
465.9M
525.3M
IPO Year
2010
2016

Fundamental Metrics

Financial Performance
Metric
NBB
FLGT
Price
$15.66
$18.88
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$28.33
AVG Volume (30 Days)
50.8K
487.6K
Earning Date
01-01-0001
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$18,730,000.00
Revenue This Year
N/A
$10.09
Revenue Next Year
N/A
$12.18
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.95
$13.46
52 Week High
$16.62
$31.04

Technical Indicators

Market Signals
Indicator
NBB
FLGT
Relative Strength Index (RSI) 46.61 64.47
Support Level $15.51 $13.91
Resistance Level $16.04 $22.66
Average True Range (ATR) 0.23 0.86
MACD 0.00 0.22
Stochastic Oscillator 48.33 75.69

Price Performance

Historical Comparison
NBB
FLGT

About NBB Nuveen Taxable Municipal Income Fund of Beneficial Interest

Nuveen Taxable Municipal Income Fund is a closed-end fund incorporated in the United States. Its primary objective is current income through investments in taxable municipal securities; the secondary objective is to seek enhanced portfolio value and total return. The fund invests a majority of its assets in a diversified portfolio of taxable municipal securities.

About FLGT Fulgent Genetics Inc.

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.

Share on Social Networks: